2 assets in Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor

Therapeutic assets addressing Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Paltusotine Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor	Crinetics Pharmaceuticals Inc.	P3	BB (66)
Cabozantinib Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor	National Cancer Institute (NCI)	P3	NR ()